5326122025-04-012025-06-305326122025-04-012025-06-30in-capmkt:OtherExpenses1Member5326122025-04-012025-06-30in-capmkt:OtherExpenses2Member5326122025-04-012025-06-30

ItemsThatWillNotBeReclassifiedToProfitAndLoss1

5326122025-04-012025-06-30

ItemsThatWillBeReclassifiedToProfitAndLoss1

iso4217:INRiso4217:INRxbrli:shares

532612

INDOCO

NOTLISTED

INE873D01024

INDOCO REMEDIES LIMITED

Main Board

Equity

2025-04-01

2026-03-31

2025-07-24

2025-07-14

INR

Lakhs

Quarterly

First quarter

Single segment

PHARMACEUTICALS

2025-07-24

10:30:00

2025-07-24

11:50:00

false

The Company does not have any debt securities and there are no defaults on loan taken by the Company for the quarter ended 30th June, 2025. Hence the said disclsoure is not applicable to the Company.

2025-04-01

2025-06-30

Unaudited

Standalone

3925300000

55800000

3981100000

877700000

392300000

-58300000

985000000

236100000

252000000

1580300000

4265100000

-284000000

-3400000

-280600000

4100000

-276500000

184500000

-3.04

1. The unaudited Standalone Results for the Quarter ended 30th June, 2025, have been reviewed by the Audit committee and approved by the Board of Directors of the Company at its meeting held on 24th July, 2025. The Statutory Auditors have expressed an Unmodified Audit opinion on these unaudited Standalone Financial Results. 2. The figures for corresponding previous periods have been restated / regrouped wherever necessary, to make them comparable. 3. The company has only one primary reportable segment of activity, namely, Pharmaceuticals. 4. Net Sales and Income from Operations as per Secondary Segment (Geographical) is as follows: Net Sales Qtr ended Qtr ended Qtr ended Year ended & Income 30-06-2025 31-03-2025 30-06-2024 31-03-2025 from Operations (Unaudited) (Audited) (Unaudited) (Audited) India 22,256 21,639 21,331 91,598 Outside India 16,127 12,468 18,091 57,880 -------------------------------------------------------------------------------------------------------------------------- Total : 38,383 34,107 39,422 1,49,478 ============================================================== 5. The statutory auditors of the company have carried out limited review of the financial results for the quarter ended 30th June, 2025. 6. Figures for the quarter ended 31.3.2025 and 31.3.2024 represents the difference between audited figures in respect of the full financial year and published figures for the period ended 31.12.2024 (limited reviewed) and 31.12.2023 (limited reviewed). 7. (*) Exceptional items include consideration received Rs. 99.4 lacs for grant to use exclusive, perpetual and irrevocable license rights in respect of trademarks of the company.

RESEARCH & DEVELOPMENT EXPENSES

216600000

OTHER EXPENSES

1363700000

Items that will not be reclassified to profit & loss

-7500000

-1900000

Items that may be reclassified to profit or loss

12900000

3200000

4100000